-
Mashup Score: 0FDA approves Anktiva for certain patients with bladder cancer - 2 hour(s) ago
The FDA approved nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guerin for the treatment of certain patients with bladder cancer, according to a press release from the manufacturer.The indication applies to individuals with Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 38ctDNA and bladder cancer: Current understanding and beyond - 4 day(s) ago
Urologist James Catto asks oncologist Thomas Powles key questions on the role of ctDNA in the understanding of urothelial cancer and its potential to
Source: www.springermedicine.comCategories: General Medicine News, Onc News and JournalsTweet-
ctDNA🧬and #BladderCancer: Current Understanding and Beyond Expert Commentary by our @OncoAlert 🚨faculty @tompowles1 🇬🇧 & Dr. James Catto 🇬🇧 Link: https://t.co/eV8Gu5FYrH Out by our Collaborators at @springer_med Pinging OncoAlert GU Faculty: @montypal @crisbergerot… https://t.co/gSTEeodFmb https://t.co/bvR90Tm0ac
-
-
Mashup Score: 6Empowering Bladder Cancer Care: A Formal Partnership between IBCG and UroToday in the Era of Expanding Therapies - 6 day(s) ago
The International Bladder Cancer Group (IBCG) and UroToday, optimizing bladder cancer patient care, AUA-IBCG Bladder Cancer Forum, bladder cancer education, enfortumab vedotin-ejfv in combination with pembrolizumab.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0The Jack Birch Unit welcome Johns Hopkins Professor - 7 day(s) ago
The Jack Birch Unit were visited by Dr David McConkey, the Director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medical School.
Source: www.york.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 38ctDNA and bladder cancer: Current understanding and beyond - 7 day(s) ago
Urologist James Catto asks oncologist Thomas Powles key questions on the role of ctDNA in the understanding of urothelial cancer and its potential to
Source: www.springermedicine.comCategories: General Medicine News, Onc News and JournalsTweet-
ctDNA🧬and #BladderCancer: Current Understanding and Beyond Expert Commentary by our @OncoAlert 🚨faculty @tompowles1 🇬🇧 & Dr. James Catto 🇬🇧 Link: https://t.co/eV8Gu5FYrH Out by our Collaborators at @springer_med Pinging OncoAlert GU Faculty: @montypal @crisbergerot… https://t.co/gSTEeodFmb https://t.co/bvR90Tm0ac
-
-
Mashup Score: 19The Jack Birch Unit welcome Johns Hopkins Professor - 7 day(s) ago
The Jack Birch Unit were visited by Dr David McConkey, the Director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medical School.
Source: www.york.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg - 11 day(s) ago
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. EV-302 introduces a combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, an anti-PD-1 inhibitor…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The EV-302 study and implications for metastatic #BladderCancer care. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss a possible new standard of care for metastatic urothelial cancer, significantly improving patient outcomes > https://t.co/shpMxDA8FO https://t.co/LHcSFJqyfl
-
-
Mashup Score: 1Bladder Cancer: Treatment Options and Managing Adverse Effects - 14 day(s) ago
Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 38ctDNA and bladder cancer: Current understanding and beyond - 15 day(s) ago
Urologist James Catto asks oncologist Thomas Powles key questions on the role of ctDNA in the understanding of urothelial cancer and its potential to
Source: www.springermedicine.comCategories: General Medicine News, Onc News and JournalsTweet-
ctDNA🧬and #BladderCancer: Current Understanding and Beyond Expert Commentary by our @OncoAlert 🚨faculty @tompowles1 🇬🇧 & Dr. James Catto 🇬🇧 Link: https://t.co/eV8Gu5FYrH Out by our Collaborators at @springer_med Pinging OncoAlert GU Faculty: @montypal @crisbergerot… https://t.co/gSTEeodFmb https://t.co/bvR90Tm0ac
-
The FDA approved nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guerin for the treatment of certain patients with bladder cancer, according to a press release from @ImmunityBio. #BladderCancer Read more👇 https://t.co/89YwzSy3kl